Identifying potential combinatorial mechanism between paclitaxel and Almonertinib in lung cancer through multi-omics integration
Year: 2026
Type: article
Abstract: Combination therapy using epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and cytotoxic chemotherapy is a promising strategy to overcome resistance in non-small cell lung cancer (NSCLC). However, the complicated molecular mechanisms remain elusive. Here, we employed an integrated multi-omics approach to dissect the molecular responses to the third-generation EGFR-TKI Almonertinib (Alm) and paclitaxel (PTX) and their combination in EGFR-mutant NSCLC cells. Transcriptomic and metabolomic profiling revealed that the combination therapy elicits an unique molecular signature distinct from either monotherapy alone. We identified a specific gene cluster (C8) that was suppressed only by the drug combination, and mainly enriched in cell cycle, DNA replication and mitochondrial function. The downregulation of these processes was validated in H1975 cells, and key genes (e.g., XRCC2 , SKA3 , TOMM40 ) also exhibited prognostic relevance. Meanwhile, metabolomic analysis uncovered a combination-specific blockade of mitochondrial fatty acid oxidation, evidenced by L-Carnitine depletion and accumulation of Hexanoyl-L-Carnitine and Oleoyl-L-Carnitine. This work demonstrates the potential combination interaction of Alm and PTX, converging on the suppression of cell cycle and the induction of carnitine metabolism blockage. Our findings provide a profound mechanistic rationale for this combination therapy.
Source: Scientific Reports
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,690
Award: G5663147001
OpenAlex ID: W7228825992
